ABSTRACT
Background: Patients with primary humoral immunodeficiency are more prone to invasive as well as recurrent pneumococcal infections. Therefore, anti-pneumococcal vaccination including the 13-valent conjugate vaccine is recommended. Nevertheless, to date, no data is available on immunogenicity of this vaccine in this population. Objective: To assess the immunogenicity and the persistence of protection up to one year after a 13-valent pneumococcal conjugate vaccine in patients with primary humoral immunodeficiency. Methods: Twenty-nine patients with common variable immunodeficiency or IgG subclass deficiency were vaccinated. Immune response and immune protection at baseline as well as at one, six and twelve months after vaccination were evaluated by measuring specific IgG serum concentrations (ELISA), and opsonophagocytic activities directed against selected pneumococcal (MOPA). Results: By ELISA, half of the patients had protective IgG concentrations before vaccination, 35.7% showed an immune response one month after vaccination, 71.4%, 66.7% and 56.0% of the patients were protected at one, six and twelve months respectively. Conversely, by MOPA, 3.4% of the patients were protected at baseline, 10.7% showed an immune response and 28.6%, 48.2% and 33.3% were protected at one, six and twelve months respectively. IgG subclass deficiency, Ig replacement therapy and higher IgG2 concentrations at diagnosis were associated with long-term protection. Conclusion: Pneumococcal conjugate vaccine improves immune protection and antibodies' functionality in a subset of patients with primary immunodeficiency. Prime-boost vaccine strategy needs to be better and individually adapted.
Subject(s)
Common Variable Immunodeficiency/immunology , Common Variable Immunodeficiency/therapy , IgG Deficiency/immunology , IgG Deficiency/therapy , Pneumococcal Vaccines/therapeutic use , Adult , Aged , Antibodies, Bacterial/blood , Antibody Specificity , Female , Humans , Immunoglobulin G/blood , Immunoglobulin G/classification , Male , Middle Aged , Phagocytosis/immunology , Pneumococcal Infections/immunology , Pneumococcal Infections/prevention & control , Serogroup , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/immunology , Time Factors , Vaccines, Conjugate/therapeutic use , Young AdultABSTRACT
Primary antibody deficiencies (PAD) are the most prevalent group of primary immunodeficiencies (PID) in adults and immunoglobulin replacement therapy (IRT) is the mainstay therapy to improve clinical outcomes. IRT is, however, expensive and, in minor PAD, clear recommendations concerning IRT are lacking. We conducted a retrospective real-life study to assess the effectiveness of low-dose IRT in minor PAD on 143 patients fulfilling European Society for Immunodeficiencies (ESID) diagnostic criteria for immunoglobulin (Ig)G subclass deficiency (IgGSD) or unclassified antibody deficiency (UAD). All patients were treated with intravenous low-dose IRT (0.14 ± 0.06 g/kg/month). Immunoglobulin (Ig) classes and IgG subclasses were measured at baseline and after 1 year of IRT. The annual rate of total infections, upper respiratory tract infections (URTI), lower respiratory tract infections (LRTI) and hospitalizations was measured at baseline and after 1 and 2 years of IRT. After 1 year of IRT significant improvement was demonstrated in: (a) serum IgG (787.9 ± 229.3 versus 929.1 ± 206.7 mg/dl; p < 0.0001); (b) serum IgG subclasses (IgG1 = 351.4 ± 109.9 versus 464.3 ± 124.1, p < 0.0001; IgG2 = 259.1 ± 140 versus 330.6 ± 124.9, p < 0.0001; IgG3 = 50.2 ± 26.7 versus 55.6 ± 28.9 mg/dl, p < 0.002); (c) annual rate of total infections (5.75 ± 3.87 versus 2.13 ± 1.74, p < 0.0001), URTI (1.48 ± 3.15 versus 0.69 ± 1.27; p < 0.005), LRTI (3.89 ± 3.52 versus 1.29 ± 1.37; p < 0.0001) and hospitalizations (0.37 ± 0.77 versus 0.15 ± 0.5; p < 0.0002). The improvement persisted after 2 years of IRT. No significant improvement in URTI annual rate was noted in UAD and in patients with bronchiectasis. In conclusion, low-dose IRT can improve clinical outcomes in UAD and IgGSD patients, providing a potential economical advantage over the standard IRT dose.
Subject(s)
IgG Deficiency/therapy , Immunoglobulin G/administration & dosage , Immunoglobulins, Intravenous/therapeutic use , Primary Immunodeficiency Diseases/therapy , Aged , Bronchiectasis/complications , Female , Hospitalization/statistics & numerical data , Humans , Immunoglobulin G/blood , Male , Middle Aged , Respiratory Tract Infections/epidemiology , Retrospective StudiesSubject(s)
Asthma/immunology , COVID-19/immunology , Common Variable Immunodeficiency/immunology , IgG Deficiency/immunology , Obesity, Morbid/immunology , Staphylococcal Infections/immunology , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/therapeutic use , Adult , Alanine/analogs & derivatives , Alanine/therapeutic use , Antiviral Agents/therapeutic use , Asthma/pathology , Asthma/therapy , Asthma/virology , COVID-19/pathology , COVID-19/therapy , COVID-19/virology , Common Variable Immunodeficiency/pathology , Common Variable Immunodeficiency/therapy , Common Variable Immunodeficiency/virology , Fatal Outcome , Humans , IgG Deficiency/pathology , IgG Deficiency/therapy , IgG Deficiency/virology , Immunization, Passive , Immunoglobulin G/blood , Immunoglobulins, Intravenous/therapeutic use , Male , Methicillin-Resistant Staphylococcus aureus , Obesity, Morbid/pathology , Obesity, Morbid/therapy , Obesity, Morbid/virology , SARS-CoV-2 , Staphylococcal Infections/pathology , Staphylococcal Infections/therapy , Staphylococcal Infections/virology , COVID-19 SerotherapyABSTRACT
BACKGROUND: The effects of intravenous immunoglobulin G replacement on perceived health and infection susceptibility of patients suffering from immunoglobulin G (IgG) deficiencies should be evaluated in a prospective analysis. METHODS: Patients with symptomatic primary or secondary IgG deficiencies were interviewed prior to the first IgG infusion (t0) and over the course of their treatment (t1 - t6). The respondents rated their current health using a 100 point scale (EQ-5D-5L), ranging from 0 ('worst imaginable health') to 100 ('best imaginable health'). The patients also provided information on the frequency of infections and of infections requiring antibiotics in the past 8 weeks. A healthy control group (CG) without oncologic diseases answered the questions once. RESULTS: One hundred six patients with a median age of 65 years (21-85 years) were investigated. The median serum IgG concentration changed from 500 mg/dl (t0) to 772 mg/dl (t6). The mean number of infections and of infections requiring antibiotics decreased during IgG replacement significantly. Current health according to EQ-5D-5L improved from 57 (t0) to 68 (t6), compared to 73 in the CG. CONCLUSION: During the course of IgG replacement patients reported fewer and less severe infections. Their health assessment improved but still was inferior to the healthy CG.
Subject(s)
IgG Deficiency/therapy , Immunoglobulins, Intravenous/therapeutic use , Infections/epidemiology , Adult , Aged , Aged, 80 and over , Female , Health Status , Humans , IgG Deficiency/epidemiology , Male , Middle Aged , Perception , Prospective Studies , Severity of Illness Index , Young AdultABSTRACT
The number of people suffering from the new coronavirus SARS-CoV-2 continues to rise. In SARS-CoV-2, superinfection with bacteria or fungi seems to be associated with increased mortality. The role of co-infections with respiratory viral pathogens has not yet been clarified. Here, we report the course of COVID-19 in a CLL patient with secondary immunodeficiency and viral co-infection with parainfluenza.
Subject(s)
COVID-19/complications , Coinfection/complications , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Paramyxoviridae Infections/complications , Antibodies, Viral/blood , COVID-19/immunology , COVID-19/therapy , Humans , IgG Deficiency/complications , IgG Deficiency/immunology , IgG Deficiency/therapy , Immunoglobulins, Intravenous/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Male , Middle Aged , Pandemics , SARS-CoV-2/immunology , Spike Glycoprotein, Coronavirus/immunologyABSTRACT
Immune dysfunction attributed to hypogammaglobulinaemia is common in chronic lymphocytic leukaemia (CLL) and infection is a major contributor to morbidity and mortality. A higher incidence of multiple immunoglobulin and immunoglobulin G (IgG) subclass deficiency was associated with more advanced disease (P < 0·001 and P < 0·001, respectively) in a cohort of 147 CLL patients. Multiple immunoglobulin and IgG subclass deficiency were significantly associated with shorter treatment-free survival (TFS) (P < 0·001 and P = 0·006, respectively). The association between disease stage and immune dysfunction demonstrated by these data suggest aspects of immune deficiency correlate with disease severity and may be associated with shorter TFS in CLL.
Subject(s)
IgG Deficiency , Immunity, Humoral , Leukemia, Lymphocytic, Chronic, B-Cell , Aged , Disease-Free Survival , Female , Humans , IgG Deficiency/blood , IgG Deficiency/immunology , IgG Deficiency/mortality , IgG Deficiency/therapy , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/mortality , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Male , Middle Aged , Survival RateABSTRACT
BACKGROUND: Lymphocytes have been shown to play an important role in the pathophysiology of acute ischemic stroke, but the properties of B cells remain controversial. The aim of this study was to unravel the role of B cells during acute cerebral ischemia using pharmacologic B cell depletion, B cell transgenic mice, and adoptive B cell transfer experiments. METHODS: Transient middle cerebral artery occlusion (60 min) was induced in wild-type mice treated with an anti-CD20 antibody 24 h before stroke onset, JHD -/- mice and Rag1 -/- mice 24 h after adoptive B cell transfer. Stroke outcome was assessed at days 1 and 3. Infarct volumes were calculated from 2,3,5-triphenyltetrazolium chloride (TTC)-stained brain sections, and neurological scores were evaluated. The local inflammatory response was determined by real-time PCR and immunohistochemistry. Apoptosis was analyzed by TUNEL staining, and astrocyte activation was revealed using immunohistochemistry and Western blot. RESULTS: Pharmacologic depletion of B cells did not influence infarct volumes and functional outcome at day 1 after stroke. Additionally, lack of circulating B cells in JHD -/- mice also failed to influence stroke outcome at days 1 and 3. Furthermore, reconstitution of Rag1 -/- mice with B cells had no influence on infarct volumes. CONCLUSION: Targeting B cells in experimental stroke did not influence lesion volume and functional outcome during the acute phase. Our findings argue against a major pathophysiologic role of B cells during acute ischemic stroke.
Subject(s)
B-Lymphocytes/pathology , Brain/pathology , Infarction, Middle Cerebral Artery/pathology , Actins/metabolism , Adoptive Transfer/methods , Animals , Brain Edema/etiology , Cytokines/genetics , Cytokines/immunology , Cytokines/metabolism , Disease Models, Animal , GTPase-Activating Proteins/metabolism , Gene Expression Regulation , Glial Fibrillary Acidic Protein/metabolism , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , IgG Deficiency/immunology , IgG Deficiency/pathology , IgG Deficiency/therapy , Immunoglobulin G/pharmacology , Immunoglobulin Heavy Chains/genetics , Immunoglobulin Heavy Chains/metabolism , Infarction, Middle Cerebral Artery/complications , Infarction, Middle Cerebral Artery/genetics , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Phosphopyruvate Hydratase/metabolismABSTRACT
Introducción : Estudios previos muestran que la infusión de inmunoglobulina G (IgG) subcutánea (SC) presenta una eficacia similar a la IgG endovenosa (EV)para prevenir las infecciones en enfermos con inmunodeficiencias primarias (IDP),predominantemente de anticuerpos con deficiencias de IgG y que este tratamiento es seguro y bien tolerado. Objetivo : Evaluar la seguridad, efectividad y tolerancia del tratamiento con IgG SC en un grupo de pacientes con IDP con deficiencias de IgG demostrada, previamente tratados con IgG EV. Métodos : Se realizó un estudio multicéntrico de remplazo en la administración de IgG EV (Intacglobin, de producción nacional) a IgG SC (Gammanorm, Octhapharma) en pacientes con IDP con deficiencia de IgG. Se incluyeron 6 enfermos; 3 niños y 3 adultos, procedentes de diferentes instituciones del país. La dosis de IgG SC fue similar a la dosis global mensual previa de IgG EV, administrada en 4 dosis divididas con valor promedio de 108 mg/kg (rango entre 100-200) semanal, durante 36 semanas. Resultados : En los enfermos que no recibieron tratamiento con IgG EV y presentaban valores muy disminuidos, los niveles de IgG sérica alcanzaron valores normales para la edad. En el resto de los pacientes, que llevaban tratamiento con IgGEV en la semana anterior al estudio, los niveles de IgG sérica se incrementaron o se mantuvieron superiores a 7 g/L dentro del rango normal. En todos los enfermos disminuyó la frecuencia y gravedad de las infecciones;durante el período de infusión de IgG SC,la tasa de infección disminuyó de 1.7 infecciones/sujeto/año a 0.5 y las infecciones fueron leves con buena respuesta al tratamiento. Todos los enfermos mantienen la administración de IgG SC domiciliaria con una buena respuesta. Conclusiones: El tratamiento de remplazo es bien tolerado y constituye una alternativa terapéutica efectiva para los enfermos con IDP(AU)
Subject(s)
Humans , Common Variable Immunodeficiency/therapy , Immunoglobulin G/therapeutic use , Cuba , IgG Deficiency/therapyABSTRACT
No disponible
Subject(s)
Humans , Female , Adult , IgG Deficiency/complications , IgG Deficiency/diagnosis , IgG Deficiency/therapy , Immunoglobulin G/analysis , Immunoglobulin G , IgG Deficiency/pathologyABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Neutropenia/complications , Neutropenia/diagnosis , Neutropenia/therapy , IgG Deficiency/complications , IgG Deficiency/diagnosis , IgG Deficiency/immunology , IgG Deficiency/physiopathology , IgG Deficiency/therapy , Autoimmunity/immunology , Autoimmunity/physiology , Colonoscopy/methods , Colonoscopy/trendsSubject(s)
Immunity, Humoral/immunology , Immunologic Deficiency Syndromes/immunology , Agammaglobulinemia/diagnosis , Agammaglobulinemia/immunology , Agammaglobulinemia/therapy , Humans , IgA Deficiency/diagnosis , IgA Deficiency/immunology , IgA Deficiency/therapy , IgG Deficiency/diagnosis , IgG Deficiency/immunology , IgG Deficiency/therapy , Immunologic Deficiency Syndromes/diagnosis , Immunologic Deficiency Syndromes/therapyABSTRACT
INTRODUCTION: An investigational 10% liquid intravenous immunoglobulin (IVIG) was studied in 63 patients with primary immunodeficiency (PID) at 15 study sites. METHODS: Patients were treated every 3 or 4 weeks with 254-1029 mg/kg/infusion of IVIG. RESULTS: Overall, Biotest-IVIG infusions were well tolerated. The proportion of infusions that were associated with adverse events during infusion, and up to 72 h after infusion, including those unrelated to study product, was 27.7% with an upper 95% confidence limit ≤30.6%. Two serious bacterial infections (SBIs) were observed resulting in a serious bacterial infection rate of 0.035 per person per year and an upper one-sided 99% confidence limit of ≤0.136 SBI/patient/year. The number of days of work or school missed due to infection were relatively low at 2.28 days/patient/year. Two patients were hospitalized for infection producing a rate of 0.21 hospitalization days/patient/year. The IgG half-life was approximately 30 days with variation among individuals. CONCLUSIONS: Pharmacokinetic parameters of specific antibody activities were essentially the same as those of total IgG. Biotest-IVIG is safe and effective in the treatment of PID.
Subject(s)
Agammaglobulinemia/therapy , Common Variable Immunodeficiency/therapy , Genetic Diseases, X-Linked/therapy , IgG Deficiency/therapy , Immunoglobulins, Intravenous , Adolescent , Adult , Aged , Bacterial Infections/immunology , Bacterial Infections/prevention & control , Child , Female , Humans , IgG Deficiency/genetics , Immunoglobulins, Intravenous/administration & dosage , Immunoglobulins, Intravenous/adverse effects , Immunoglobulins, Intravenous/pharmacokinetics , Immunoglobulins, Intravenous/therapeutic use , Male , Middle Aged , Young AdultABSTRACT
Primary antibody deficiencies (PADs) are the most common primary immunodeficiencies and are characterized by a defect in the production of normal amounts of antigen-specific antibodies. PADs represent a heterogeneous spectrum of conditions, ranging from often asymptomatic selective IgA and IgG subclass deficiencies to the severe congenital agammaglobulinemias, in which the antibody production of all immunoglobulin isotypes is severely decreased. Apart from recurrent respiratory tract infections, PADs are associated with a wide range of other clinical complications. This review will describe the pathophysiology, diagnosis, and treatment of the different PADs.
Subject(s)
Agammaglobulinemia , Antibodies/blood , IgA Deficiency , IgG Deficiency , Agammaglobulinemia/complications , Agammaglobulinemia/diagnosis , Agammaglobulinemia/physiopathology , Agammaglobulinemia/therapy , Child , Diagnosis, Differential , Humans , IgA Deficiency/complications , IgA Deficiency/diagnosis , IgA Deficiency/physiopathology , IgA Deficiency/therapy , IgG Deficiency/complications , IgG Deficiency/diagnosis , IgG Deficiency/physiopathology , IgG Deficiency/therapy , Respiratory Tract Infections/immunology , Treatment OutcomeABSTRACT
The immune response consists of two main components: humoral immunity represented by B lymphocytes and cellular immunity maintained by the T lymphocytes. Immunoglobulins, produced by B-lymphocytes, are the main mediators of humoral immunity, and deficiencies at this level affect the body's response to infection. Plasmocytes produce nine antibody izotypes: immunoglobulins G (IgG1, IgG2, IgG3, IgG4), immunoglobulins M (IgM), immunoglobulins A (IgA1, IgA2), immunoglobulins D (IGD) and immunoglobulins E (IgE). Primary hypogammaglobulinemias are characterized by the occurrence of recurrent infections and, paradoxically, by the occurrence of autoimmune diseases. Characteristic for these diseases is that symptoms occur at 7-9 months after birth, when transplacental antibody titers transmitted from the mother decrease, and the infant's body is unable to synthesize them to normal levels. Primary hypogammaglobulinemias are transmitted genetically, but mutations at the molecular level are still not fully understood. The most common are: Bruton agammaglobulinemia, transient newborn hypogammaglobulinemia, selective immunoglobulin deficiency and variable common immunodeficiency. Treatment consists of monthly antibiotics and immunoglobulins, depending on antibody titers (except for IgA deficiency).
Subject(s)
B-Lymphocytes/immunology , Immunologic Deficiency Syndromes/diagnosis , Immunologic Deficiency Syndromes/therapy , Common Variable Immunodeficiency/diagnosis , Common Variable Immunodeficiency/therapy , Humans , IgA Deficiency/diagnosis , IgA Deficiency/therapy , IgG Deficiency/diagnosis , IgG Deficiency/therapy , Immunoglobulin M/deficiency , PrognosisABSTRACT
IgG subclass deficiencies are common immune system disorders during childhood. The aim of this retrospective study was to review clinical findings and laboratory results of patients with IgG subclass deficiencies in order to determine the changes in serum IgG subclass levels during follow-up, the percentage and time span until normalization of the IgG subclass levels to age-corresponding normal levels, the type of infections incurred and the benefits of prophylaxis. Among the 59 pediatric patients reviewed, the most frequent defect was an IgG3 subclass deficiency (77%). Nine percent of the patients had an isolated IgG2 deficiency and 14% had an IgG2+G3 deficiency. The most common clinical presentations were recurrent upper respiratory tract infections, followed by pneumonia, acute gastroenteritis and urinary tract infections. Atopy was present in 15% of the patients. Ninety percent of the patients were given a prophylactic treatment (benzathine penicillin, oral antibiotics, oral bacterial lysate or intravenous immunoglobulin). The frequency of recurrent infections decreased from 13.4 +/- 7.4 per year to 5.7 +/- 3.9 in patients receiving a prophylactic regimen. Serum IgG subclass levels reached normal ranges in 30% of the patients in the IgG3 deficiency group and in 35.7% of the patients in the IgG2+G3 deficiency group. Patients with an isolated IgG2 deficiency did not reach age-related normal levels during the study period. Our study shows that IgG subclass levels may normalize in 30 to 40% of patients at about 6 years of age. We emphasize the need of monitoring IgG levels together with the clinical symptomatology in affected individuals and initiate preventive measures when appropriate.
Subject(s)
IgG Deficiency/blood , Immunoglobulin G/blood , Monitoring, Physiologic/methods , Child , Child, Preschool , Female , Humans , IgG Deficiency/epidemiology , IgG Deficiency/immunology , IgG Deficiency/therapy , Immunoglobulin G/immunology , Infant , Male , Turkey/epidemiologySubject(s)
IgG Deficiency/diagnosis , Immunoglobulin G/blood , Immunologic Deficiency Syndromes/diagnosis , Adolescent , Adult , Agammaglobulinemia/blood , Agammaglobulinemia/diagnosis , Agammaglobulinemia/therapy , B-Lymphocytes/cytology , B-Lymphocytes/immunology , CD4 Lymphocyte Count , CD8-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/immunology , Child , Child, Preschool , Common Variable Immunodeficiency/blood , Common Variable Immunodeficiency/diagnosis , Common Variable Immunodeficiency/therapy , Dysgammaglobulinemia , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/diagnosis , Genetic Diseases, X-Linked/therapy , Humans , Hyper-IgM Immunodeficiency Syndrome, Type 1/blood , Hyper-IgM Immunodeficiency Syndrome, Type 1/diagnosis , Hyper-IgM Immunodeficiency Syndrome, Type 1/therapy , IgG Deficiency/blood , IgG Deficiency/therapy , Immunization, Passive , Immunoglobulin A/blood , Immunoglobulin M/blood , Immunologic Deficiency Syndromes/blood , Immunologic Deficiency Syndromes/therapy , Infant , Infant, Newborn , Nephelometry and Turbidimetry , Reference ValuesABSTRACT
A seven-year-old white male presented with recurrent bouts of paranasal sinusitis, streptococcal pharyngotonsillitis, lower respiratory tract infections, continuous low-grade fever, and conjunctivitis, which required frequent use of antibiotics over a period of two years. A careful review of systems also revealed a six-month history of arthralgia affecting his knees, elbows, and hands, which limited his daily activities. Prominent in the history were recurrent bouts of a generalized salmon-red, nonpruritic rash, which was most pronounced on the face and trunk and which was exacerbated by fever. His past medical history revealed severe bouts of gastroesophageal reflux disease, chronic intermittent bloody mucous diarrhea, and atopic dermatitis. A detailed review of the patient's family pedigree over five generations revealed a strong genetic predisposition for autoimmune diseases of several types. His physical examination revealed a thin, pale, chronically ill-appearing male, bilateral conjunctivitis, and pale nasal mucosae with no lymphadenopathy, organomegaly, arthritis, or rash. All laboratory results were unremarkable except for a positive rheumatoid factor and a suboptimal antibody response to immunization with pneumococcal vaccine. A diagnosis of juvenile rheumatoid arthritis of the systemic onset type was established, and, based upon his humoral immune deficiency, treatment with intravenous immunoglobulin was initiated with remarkable improvement in his symptomatology.
Subject(s)
Arthritis, Juvenile/diagnosis , IgG Deficiency/diagnosis , Arthralgia/etiology , Arthritis, Juvenile/complications , Arthritis, Juvenile/therapy , Child , Humans , IgG Deficiency/complications , IgG Deficiency/therapy , Male , Pedigree , Respiratory Tract Infections/etiologyABSTRACT
In a retrospective analysis of our patient population, 20 difficult-to-treat patients with asthma were found to have clinical and laboratory evidence of specific antibody deficiency, and several had mild hypogammaglobulinemia. Intravenous immunoglobulin replacement therapy at 400-600 mg/kg every 3-4 weeks gave remarkable clinical benefits, with reduction in morbidity, number of hospitalizations, steroid therapy, and number of respiratory infections. We believe that, in this group of patients, the use of intravenous immunoglobulin perhaps allows the achievement of asthma prevention rather than an amelioration of inflammation.
Subject(s)
Antibody Formation , Asthma/immunology , IgG Deficiency/therapy , Immunoglobulins, Intravenous/therapeutic use , Adult , Aged , Asthma/physiopathology , Diphtheria Toxoid/immunology , Female , Forced Expiratory Volume , Humans , IgG Deficiency/complications , Male , Middle Aged , Peak Expiratory Flow Rate , Pneumococcal Vaccines/immunology , Tetanus Toxoid/immunologyABSTRACT
No disponible
No disponible
